Clinical Trials
198 trialsPhase 1/2 Study of UI-102 in Selected Advanced Cancers
United Immunity, co., Ltd.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers
Neovia Oncology Ltd.
ALIGN
University of Colorado, Denver
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
SONATA 2
University of Rochester
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Pilot Trial of Spiritual Care Interventions for Patients With Cancer
Weill Medical College of Cornell University
Development and Pilot Trial of Focused ACT (FACT) for Patients With Advanced Cancer
M.D. Anderson Cancer Center
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
M.D. Anderson Cancer Center
Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy
M.D. Anderson Cancer Center
Trial of Spiritual Care Interventions for Patients With Cancer
Weill Medical College of Cornell University
Care Coach-led Integrated Palliative Surgical Oncology and Rehabilitation Care Model for Advanced Cancer Patients
Singapore General Hospital
Care Planning Framework in Advanced Cancer (ABC123)
University of Colorado, Denver
RP-6306 in Patients With Advanced Cancer
Canadian Cancer Trials Group
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
Bristol-Myers Squibb
CCST2
Duke University
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Psilocybin Therapy in Advanced Cancer
NYU Langone Health
Clinical Trial of TQB3002 in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
CheckMate 577
Bristol-Myers Squibb
A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors
Bristol-Myers Squibb
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Agenus Inc.
An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort
Prescient Therapeutics, Ltd.
Phase 1 Study of AWT020 in Advanced Cancer
Anwita Biosciences
MATTERS
ElmediX
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
iCALM
University Health Network, Toronto
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
HC Biopharma Inc.
PCRSS
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer
Memorial Sloan Kettering Cancer Center
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
Shanghai Allink Biotherapeutics Co., Ltd.
Virtual Dignity Therapy for Palliative Care Patients With Advanced Cancer
Mayo Clinic
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors
Akeso
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
Akeso
MSPD
Institut du Cancer de Montpellier - Val d'Aurelle
Videos for Advance Care Planning in Young Adults
Dana-Farber Cancer Institute
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
Viracta Therapeutics, Inc.
A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer
Eli Lilly and Company
EMPallA
NYU Langone Health
The PediQUEST Response Intervention Study
Massachusetts General Hospital
PRIMO
Gustave Roussy, Cancer Campus, Grand Paris
TAX-TORC
Royal Marsden NHS Foundation Trust
ComPAKT
Royal Marsden NHS Foundation Trust